01466nas a2200289   4500000000100000008004100001260001300042653001200055653002600067653001100093653002100104653000900125653000900134653002400143653001500167653002500182653001500207100001200222700001500234245009700249856005900346300001100405490000700416050003200423520070700455022001401162       1992                            d  c1992 Jun10aAnimals10aAnti-Infective Agents10aFemale10aFluoroquinolones10aFoot10aMice10aMice, Inbred BALB C10aMice, Nude10aMycobacterium leprae10aQuinolones1 aGidoh M1 aTsutsumi S00aActivity of sparfloxacin against Mycobacterium leprae inoculated into footpads of nude mice.  uhttp://leprev.ilsl.br/pdfs/1992/v63n2/pdf/v63n2a03.pdf  a108-160 v63  aInfolep Library - available3 a<p>The antileprosy activity of a new quinolone, sparfloxacin, was examined in the nude mouse footpad model. By serial dosing (once a day, 5 or 6 times per week, during the 3rd-5th months postinoculation), 10 mg/kg of sparfloxacin displayed bactericidal-type activity and bacteriostatic activity was present at daily doses of 5 and 2 mg/kg. By intermittent dosing (once a day, twice weekly at daily doses of 10 and 20 mg/kg or once weekly at a daily dose of 30 mg/kg, during the 3rd-5th months postinoculation), sparfloxacin markedly inhibited the growth of leprosy bacilli with slight remultiplication at later stages. Sparfloxacin seems to be worth studying clinically as a novel antileprosy drug.</p>  a0305-7518